<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04616625</url>
  </required_header>
  <id_info>
    <org_study_id>1632548</org_study_id>
    <nct_id>NCT04616625</nct_id>
  </id_info>
  <brief_title>Cardiovascular Effects of Prenatal Methamphetamine Exposure</brief_title>
  <official_title>Cardiovascular Effects of Prenatal Methamphetamine Exposure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Davis</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Adventist Health and Rideout</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, Davis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Methamphetamine (MA) is one of the commonly used drugs during pregnancy. Cardiovascular&#xD;
      effects of MA include elevated blood pressure, acute vasospasm, atherosclerotic disease,&#xD;
      structural and electrical remodeling of cardiac tissue leading to arrhythmias and heart&#xD;
      failure, and pulmonary hypertension.1 In addition, MA can cause neurotoxicity with harmful&#xD;
      effects on neurodevelopment in the children who had prenatal exposure.5-8 Currently neonatal&#xD;
      providers do not perform detailed cardiovascular evaluation in newborn period or long term&#xD;
      neurodevelopmental assessments as outpatient for the newly born infants with prenatal&#xD;
      exposure to MA, and they do not qualify for early intervention. The goal of the investigators&#xD;
      is to perform detailed cardiovascular evaluation in neonatal period and estimate baseline&#xD;
      prevalences and follow up with developmental and cardiovascular assessment using a&#xD;
      questionnaire at 12 months in a cohort of neonates enriched with those who had prenatal&#xD;
      exposure to MA.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 5, 2020</start_date>
  <completion_date type="Anticipated">June 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Estimation of prevalence of MA use among births</measure>
    <time_frame>Through study completion, an average of 2 years.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluation of effects of prenatal MA exposure on neonatal cardiovascular status.</measure>
    <time_frame>Through study completion, an average of 2 years.</time_frame>
    <description>Perfusion index by pulse-oximeter, heart function by echocardiogram, EKG and detailed cardiac exam in the newborn period between 24-48 hours after birth.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Infant's neurodevelopmental outcome and general assessment at 12 months of age.</measure>
    <time_frame>Through study completion, an average of 2 years.</time_frame>
    <description>Phone call with parent to assess the infant's neurodevelopment at 12 months of age using &quot;Ages and Stages&quot; questionnaire with parent and/or pediatrician, assessment of general health, nutrition and cardiovascular status (BP measurement) by phone call with pediatrician</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">42</enrollment>
  <condition>Methamphetamine Abuse</condition>
  <condition>Newborn Complication &amp;#X7C; Patient &amp;#X7C; Neonatalology</condition>
  <arm_group>
    <arm_group_label>Methamphetamine exposed</arm_group_label>
    <description>Infants born to mothers with prenatal history of MA use during current pregnancy and/or positive meconium toxicology positive for MA in infant.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Methamphetamine non-exposed</arm_group_label>
    <description>Infants born to mothers without prenatal history of MA use during this pregnancy and negative meconium toxicology for MA in infant.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Infants born at UCDCH and at AHRO at gestational age &gt;34 weeks. (&lt;34 weeks excluded to&#xD;
        avoid the effects of prematurity)&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Infants born at UCDCH and at AHRO at gestational age &gt;34 weeks. (&lt;34 weeks excluded to&#xD;
             avoid the effects of prematurity)&#xD;
&#xD;
          2. For the MA exposed subgroup (n=30): Infants born to mothers with prenatal history of&#xD;
             MA use during current pregnancy and/or positive meconium toxicology positive for MA in&#xD;
             infant.&#xD;
&#xD;
          3. For the MA unexposed subgroup (n=12): Infants born to mothers without prenatal history&#xD;
             of MA use during this pregnancy and negative meconium toxicology for MA in infant.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        a) Presence of congenital anomalies and known fatal conditions.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Deepika Sankaran, MD</last_name>
    <phone>3477410372</phone>
    <email>dsankaran@ucdavis.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Satyan Lakshminrusimha, MD</last_name>
    <phone>9167343891</phone>
    <email>slakshmi@ucdavis.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Adventist Health and Rideout</name>
      <address>
        <city>Marysville</city>
        <state>California</state>
        <zip>95901</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deepika Sankaran, MD</last_name>
      <phone>916-734-8672</phone>
      <email>dsankaran@ucdavis.edu</email>
    </contact>
    <contact_backup>
      <last_name>Rosa R. Pesavento</last_name>
      <phone>6508145023</phone>
      <email>rpesavento@ucdavis.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>UC Davis Children's Hospital</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rosa R. Pesavento</last_name>
      <phone>650-814-5023</phone>
      <email>rpesavento@ucdavis.edu</email>
    </contact>
    <contact_backup>
      <last_name>Catherine Rottkamp, MD PhD</last_name>
      <phone>9168165077</phone>
      <email>carrottkamp@ucdavis.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 8, 2020</study_first_submitted>
  <study_first_submitted_qc>October 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 5, 2020</study_first_posted>
  <last_update_submitted>October 29, 2020</last_update_submitted>
  <last_update_submitted_qc>October 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Methamphetamine</keyword>
  <keyword>Methamphetamine in pregnancy</keyword>
  <keyword>Cardiovascular effects of methamphetamine on newborn</keyword>
  <keyword>Effect of prenatal methamphetamine exposure on neurodevelopment</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

